Anakinra for resistant behçet uveitis: Why not?

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Emmi Dr , Giacomo ^b   Silvestri, E ^a,b   Cameli, A M ^b   Bacherini, D ^a   Vannozzi, L ^a   Squatrito, D ^a,b   Emmi, L ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; INTERLEUKIN 1; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ADULT; ANGIONEUROTIC EDEMA; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LETTER; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; URTICARIA; UVEITIS;

ADULT; BEHCET SYNDROME; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; TREATMENT OUTCOME; UVEITIS;

EID: 84884923594     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. MESQUIDA M, MOLINS B, LLORENC V et al.: Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol 2013 Jun 1. [Epub ahead of print].
2. HATEMI G, SEYAHI E, FRESKO I: Behçet's syndrome: a critical digest of the recent literature. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S80-9.
3. DINARELLO CA, SIMON A, van der MEER JW: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
4. GUL A, TUGAL-TUTKUN I, DINARELLO CA: Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-6.
5. BOTSIOS C, SFRISO P, FURLAN A et al.: Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-6.